Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 54Lymphoma, Mantle-Cell 31Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Non-Hodgkin 14Lymphoma 11Leukemia, B-Cell 7Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Leukemia 5Waldenstrom Macroglobulinemia 4Multiple Myeloma 3Recurrence 2Pancreatic Neoplasms 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Prolymphocytic 2Hematologic Neoplasms 2Cardiovascular Diseases 2Squamous Cell Carcinoma of Head and Neck 1Pyloric Stenosis, Hypertrophic 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Neuritis 1Neoplasms 1Neoplasm, Residual 1Leukemia, Hairy Cell 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1

Interventions

acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Haematological Malignancies × acalabrutinib × Clear all
NCT04630756 2025-04-09

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

AstraZeneca

Phase 1/2 Completed
40 enrolled 31 charts

Advanced Haematological Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡